Clinical Trial

Disease: Brain, Meninges, and Spinal Cord Metastatic Solid Tumors, (NCT06742593)

Disease info:

A solid tumour is an abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumours may be benign (not cancer), or malignant (cancer). Solid tumour types are named according to the type of cell they originate from. Examples of solid tumours are sarcomas, carcinomas, and lymphomas. Leukaemias (cancers of the blood) generally do not form solid tumours.

The word tumour does not always imply cancer. In discussing tumours that are malignant (cancerous), however, the term solid tumour is used to distinguish between a localised mass of tissue and leukaemia.

Frequency:
Excluding non-melanoma skin cancers, over 2 million new cancer cases are expected to be diagnosed in the US in 2025.
Official title:
A Single-arm, Dose-escalating Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetic , and Efficacy of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors
Who:

Study Contact:

Name: Shuhang Wang, MD/phD

Phone Number: +86-01087788713

Email: snowflake201@gmail.com

Principal Investigator: Ning Li, MD/phD,Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Sponsor:

Suzhou Maximum Bio-tech Co., Ltd.

Partners:
Locations:

Beijing, China, 100029

Cancer Hospital, Chinese Academy of Medical Sciences

Contact: Shuhang Wang

Phone: +86-010-87788713

Email: snowflake201@gmail.com

Study start:
Jan. 1, 2025
Enrollment:
12
Gene editing method:
CRISPR-Cas
Type of edit:
Gene insertion
Gene:
Gene expressing a CAR that targets B7-H3
Delivery method:
- Ex-vivo
Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Not yet recruiting

Last updated: Jun. 21, 2025
close
Search CRISPR Medicine